Researchers at the FAMU-FSU College of Engineering have unveiled a laboratory-developed hydrogel that could signal a breakthrough in the treatment of spinal cord injuries, according to a study published November 17, 2026 in Advanced Healthcare Materials.

Targeted Release with pH-Responsive Design

The innovation centers on a hydrogel embedded with extracellular vesicles (EVs) — microscopic packets carrying therapeutic biomolecules. These EVs are absorbed by injured spinal cord cells and can cross the tough blood-spinal cord barrier, a major challenge in treating neurological injuries. What sets the FAMU-FSU hydrogel apart is its ability to regulate particle release based on pH changes. When the hydrogel’s environment shifts from a basic pH of 9 to a neutral pH of 7, it stimulates a steady release of EVs, a feature aimed at maximizing the healing potential while reducing the abrupt particle release that hampered earlier hydrogel-based therapies.

Improved Healing in Lab Models

In laboratory tests using tissue cultures designed to mimic spinal cord wounds, the hydrogel outperformed previous methods, promoting higher rates of cellular repair compared to uncontrolled release. The study’s findings suggest that this approach could represent a substantial leap toward therapies that deliver treatment precisely when and where it is needed.

Addressing a Critical Medical Need

Spinal cord injuries affect roughly 300,000 Americans, with about 20,000 new cases reported each year. As current treatment options remain limited in their ability to promote recovery, approaches that harness the benefits of controlled, targeted therapies like EVs hold considerable promise. Earlier efforts faced difficulties in modulating therapeutic delivery, often resulting in reduced effectiveness as the cargo leaked away prematurely.

Next Steps and Unresolved Questions

While the results are promising, this technology remains in the research phase, with experiments so far limited to in vitro models rather than living organisms. Further work is planned to assess the hydrogel’s performance in more complex systems and to determine its safety and efficacy in vivo, moving toward the goal of eventual clinical use.

This research builds on a growing body of studies focused on biomaterial-based therapies for spinal injury, offering a new level of precision by leveraging pH-triggered control of nanoparticle delivery. Further validation will be required, but the announcement marks an encouraging development in regenerative medicine for spinal cord injuries.